Revenue Performance - Revenue for Q2 2024 was €14,436 thousand, a 90.2% increase from €7,579 thousand in Q2 2023[1] - Total revenue for the first half of 2024 reached €26,809 thousand, compared to €14,708 thousand in the same period of 2023, marking an 82.0% increase[1] - Revenue from collaboration agreements with GSK accounted for EUR 17,622k in the first half of 2024, up from EUR 12,756k in the same period of 2023, reflecting a 38.5% increase[13] - For the six months ended June 30, 2024, the Company recognized total revenues of EUR 26,809k, a 82.2% increase compared to EUR 14,708k for the same period in 2023[12] Losses and Expenses - Operating loss for Q2 2024 was €73,620 thousand, slightly higher than €71,801 thousand in Q2 2023[1] - Net loss for Q2 2024 was €72,543 thousand, compared to €67,414 thousand in Q2 2023, reflecting a 7.5% increase in losses[1] - Total comprehensive loss for Q2 2024 was €72,566 thousand, compared to €67,416 thousand in Q2 2023, reflecting a 7.5% increase in comprehensive losses[1] - Research and development expenses for Q2 2024 were €31,093 thousand, compared to €30,868 thousand in Q2 2023, indicating a slight increase[1] - The Company reported finance income of €2,533 thousand in Q2 2024, down from €6,197 thousand in Q2 2023[1] - The Company reported a total cost of sales of EUR 82,412k for the six months ended June 30, 2024, compared to EUR 46,489k for the same period in 2023, representing a 77.2% increase[16] - Research and development expenses increased to EUR 58,918k for the six months ended June 30, 2024, from EUR 55,118k in the same period of 2023, marking a 5.1% increase[18] - Share-based payment expenses for the six months ended June 30, 2024, totaled EUR 1,731k, down 62% from EUR 4,572k in the same period of 2023[24] Financial Position - Cash and cash equivalents decreased to €202,515 thousand as of June 30, 2024, down from €402,452 thousand at the end of 2023[3] - Total assets decreased to €556,836 thousand as of June 30, 2024, from €788,249 thousand at the end of 2023[3] - The accumulated deficit increased to €1,709,077 thousand as of June 30, 2024, compared to €1,565,981 thousand at the end of 2023[3] - The Company had contract liabilities of EUR 84,815k as of June 30, 2024, down from EUR 92,680k at December 31, 2023, indicating an 8.5% decrease[15] - The Group's trade receivables increased to EUR 18,769k as of June 30, 2024, compared to EUR 14,326k at December 31, 2023, reflecting a 31.4% increase[15] - Trade and other payables decreased by EUR 40,520k to EUR 7,513k as of June 30, 2024, from EUR 48,033k as of December 31, 2023[35] Strategic Developments - A new licensing agreement with GSK was entered into in July 2024, granting GSK full control over developing and manufacturing vaccine candidates for seasonal influenza and COVID-19[13] - CureVac and GSK entered a new licensing agreement, with CureVac receiving an upfront payment of EUR 400m and potential additional payments of up to EUR 1,050m in milestones and royalties[47] - The new agreement with GSK allows CureVac to retain exclusive rights to additional undisclosed infectious disease targets and the freedom to independently develop mRNA vaccines[47] - CureVac announced a strategic restructuring, including a workforce reduction of approximately 30%, aimed at focusing on high-value mRNA projects in oncology and other areas[48] - The restructuring is expected to decrease operational expenses by more than 30% from 2025 onward, including a reduction of personnel costs by approximately EUR 25m[48] - CureVac anticipates incurring one-time restructuring charges of approximately EUR 15m, subject to various assumptions[48] Milestones and Agreements - The Company achieved a development milestone of EUR 5,000k under the GSK I collaboration in Q2 2024, contributing EUR 1,711k to revenue recognition for the first half of 2024[13] - In August 2024, CureVac invoiced a EUR 10m development milestone payment to GSK for the start of a Phase 2 study of an investigational influenza A (H5N1) vaccine candidate[49] - The avian influenza program is fully controlled by GSK under the new licensing agreement, with the vaccine candidate based on CureVac's proprietary second-generation mRNA backbone[49] Shareholder Information - The number of common shares issued and outstanding as of June 30, 2024, was 224,314,013, an increase from 223,988,675 as of December 31, 2023[23] - Dievini Hopp BioTech holding GmbH & Co. KG holds approximately 37% of CureVac's shares and voting rights, making it the de facto parent of the Group[43] Tax and Other Expenses - The effective income tax rate for the six months ended June 30, 2024, was approximately 6.1%, reflecting the use of loss carryforwards[39] - Basic loss per share for the three months ended June 30, 2024, was EUR 0.32, compared to EUR 0.30 for the same period in 2023[41] - The impairment expense recognized due to the termination of a license agreement amounted to EUR 3,248k, included in research and development expenses[29] - CureVac incurred a cost of EUR 107k related to a settlement agreement with former executive Antony Blanc, with EUR 92k paid during the six months ended June 30, 2024[46]

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for CureVac N.V. (CVAC) due to higher revenues, with a focus on how actual results compare to estimates impacting stock price [1] Earnings Expectations - CureVac is expected to report a quarterly loss of $0.28 per share, reflecting a year-over-year change of +15.2% [3] - Revenues are projected to be $10.07 million, which is an increase of 22.1% from the same quarter last year [3] Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst expectations [4] - The Most Accurate Estimate for CureVac is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +7.14%, suggesting a bullish outlook from analysts [10] Earnings Surprise Prediction - A positive Earnings ESP reading is a strong indicator of a potential earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [8] - CureVac currently holds a Zacks Rank of 3, indicating a likelihood of beating the consensus EPS estimate [11] Historical Performance - In the last reported quarter, CureVac was expected to post a loss of $0.22 per share but actually reported a loss of $0.34, resulting in a surprise of -54.55% [12] - Over the past four quarters, CureVac has only beaten consensus EPS estimates once [13] Conclusion - CureVac is viewed as a compelling candidate for an earnings beat, but investors should consider other factors before making investment decisions [16]

Core Insights - The Zacks Rank stock-rating system effectively utilizes earnings estimate revisions to classify stocks, with Zacks Rank 1 stocks achieving an average annual return of +25% since 1988 [2][4] - The recent upgrade of CureVac to Zacks Rank 2 indicates a positive shift in its earnings outlook, which is expected to positively influence its stock price [5][9] Earnings Estimate Revisions - CureVac's earnings estimates have seen a significant increase, with the Zacks Consensus Estimate rising by 111.6% over the past three months [13] - For the fiscal year ending December 2024, CureVac is projected to earn $0.07 per share, reflecting a 105.5% increase from the previous year's reported figure [7] Market Positioning - The upgrade to Zacks Rank 2 places CureVac in the top 20% of Zacks-covered stocks based on earnings estimate revisions, suggesting potential for near-term stock price appreciation [14] - The Zacks rating system maintains a balanced approach, ensuring that only the top 5% of stocks receive a 'Strong Buy' rating, which highlights the significance of CureVac's position within this framework [8][10]

Financial Performance - Total revenue for the three months ended March 31, 2024, was EUR 12,373k, an increase from EUR 7,129k in the same period of 2023, representing a growth of approximately 74.5%[55]. - The basic loss per share for the three months ended March 31, 2024, was EUR 0.31, compared to EUR 0.27 for the same period in 2023[20]. - Net loss for the period increased to EUR 70,553k for the three months ended March 31, 2024, from EUR 57,419k in the same period of 2023, representing an increase of about 22.8%[55]. - Total comprehensive loss for the period was EUR 70,609k for the three months ended March 31, 2024, compared to EUR 57,400k in the same period of 2023, indicating an increase of approximately 22.9%[55]. - The operating loss for the three months ended March 31, 2024, was EUR 73,317k, compared to an operating loss of EUR 60,355k in the same period of 2023, indicating a deterioration of approximately 21.5%[55]. Cash and Cash Equivalents - Cash and cash equivalents decreased from EUR 402,452k as of December 31, 2023, to EUR 300,152k as of March 31, 2024, a decline of 25.5%[36]. - Cash and cash equivalents at the end of the period were EUR 617,519k, up from EUR 300,152k at the end of the same period in 2023, marking an increase of approximately 105.8%[39]. - The company reported a net cash flow used in operating activities of EUR (99,586)k for the three months ended March 31, 2024, compared to EUR (96,554)k in the same period of 2023, showing a slight increase in cash outflow[39]. Share Issuance and Equity - The company issued 317,005 common shares between January and March 2024, increasing total outstanding shares to 224,305,680 as of March 31, 2024[7]. - The follow-on public offering in February 2023 raised EUR 219,832k from the sale of 27,027,028 common shares at USD 9.25 per share, with additional offering costs of EUR 14,580k[8]. - The total equity decreased from EUR 516,941k as of December 31, 2023, to EUR 446,913k as of March 31, 2024, a decline of 13.5%[36]. - CureVac's total equity as of March 31, 2024, was EUR 446,913k, a decrease from EUR 713,399k as of March 31, 2023[59]. Expenses and Provisions - Research and development expenses increased to EUR 27,825k for the three months ended March 31, 2024, compared to EUR 24,251k in the same period of 2023, reflecting a rise of about 10.6%[55]. - Research and development expenses decreased to EUR 19,119k for the three months ended March 31, 2024, from EUR 23,287k in the prior year, primarily due to reimbursements from GSK[96][95]. - The company recognized an increase in provisions related to arbitration claims by EUR 17,000k, following a ruling that awarded 65% of Celonic's claims[17]. - Other liabilities and provisions increased by EUR 8,960k during the three months ended March 31, 2024, mainly due to higher provisions[82]. Assets and Liabilities - The company reported a decrease in trade and other payables from EUR 48,033k as of December 31, 2023, to EUR 18,457k as of March 31, 2024, a reduction of 61.6%[16]. - Inventories increased from EUR 24,801k as of December 31, 2023, to EUR 26,207k as of March 31, 2024, an increase of 5.7%[36]. - Trade receivables increased to EUR 14,644k as of March 31, 2024, from EUR 14,326k as of December 31, 2023, reflecting a growth of about 2.2%[45]. - Prepaid expenses and other current assets as of March 31, 2024, amounted to EUR 22,820k, a decrease from EUR 23,763k as of December 31, 2023[105]. - The Company had tax receivables of EUR 6,813k as of March 31, 2024, down from EUR 12,881k as of December 31, 2023[105]. Agreements and Collaborations - The company invoiced EUR 5,000k to GSK for a development milestone related to a Phase 1 study of an investigational influenza A vaccine candidate[27]. - Revenue recognized under collaboration agreements with GSK for the three months ended March 31, 2024, was EUR 8,895k, compared to EUR 6,473k in the same period of 2023, reflecting an increase of about 37.3%[44]. - The company entered into a co-development and licensing agreement with The University of Texas MD Anderson Cancer Center in April 2024 to develop novel mRNA-based cancer vaccines[92]. Share-Based Payments and RSUs - Share-based payment expenses for the three months ended March 31, 2024, were EUR 487k, down from EUR 1,578k in the same period of 2023[99]. - As of March 31, 2024, the Group awarded a total of 92,701 RSUs to Supervisory Board members and 646,914 RSUs to the Executive Board and various key employees[102]. - A total of 295,390 RSUs were settled up to March 31, 2024[102]. - No options were exercised under the New VSOP plan within the three months ended March 31, 2024[103]. - Diluted earnings per share calculations excluded share options and RSUs of 1,413,112 as of March 31, 2024, due to their antidilutive effect[109]. Other Financial Information - The company acquired intangible assets amounting to EUR 4,078k during the three months ended March 31, 2024, significantly higher than EUR 134k in the same period of 2023[78]. - The increase in property, plant, and equipment during the three months ended March 31, 2024, was EUR 1,284k, compared to EUR 3,206k for the same period in 2023[104]. - The Group incurred a cost of EUR 107k related to a settlement agreement with former executive Antony Blanc in 2023, with EUR 76k paid during the three months ended March 31, 2024[111].

There are several stocks to sell now that are clinging to life support. These companies have been diluting their shares and burning cash at an alarming rate, making a successful comeback an increasingly unlikely prospect. Rather than accepting reality, management has resorted to desperate measures to keep the lights on, effectively kicking the can down the road at the expense of shareholders.Holding on to such stocks is a surefire way to watch your hard-earned capital vanish into thin air. As tempting as it ...

Table of Contents FORM 20-F CureVac N.V. Table of Contents Title of Class Number of Shares Outstanding Common shares, par value €0.12 per share 223,988,675 Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒ If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Yes ☐ No ☒ Note – Checking the ...

CureVac N.V. (NASDAQ:CVAC) Q4 2023 Earnings Conference Call April 24, 2024 9:00 AM ET Company Participants Sarah Fakih - Vice President of Corporate Communications & Investor Relations Alexander Zehnder - Chief Executive Officer Myriam Mendila - Chief Development Officer Pierre Kemula - Chief Financial Officer Marcus Dalton - Head, Intellectual Property Conference Call Participants Evan Wang - Guggenheim Roy Buchanan - Citizens JMP Mani Foroohar - Leerink Partners Umer Raffat - Evercore ISI Charlie Yang - ...

✓Recommendation for 100 µg as preferred dose in subsequent Phase 1 doseconfirmation Part B Fourth Quarter and Full-Year 2023 Financial Results and Business Update April 24, 2024 CureVac Speakers Alexander Zehnder Business Update Chief Executive Officer Myriam Mendila Program Update Chief Development Officer Pierre Kemula Financial Update Chief Financial Officer Marcus Dalton Q&A Session Head of Intellectual Property CureVac N.V. │ Fourth Quarter and Full-Year 2023 Results 2 Forward-Looking Statements The in ...

CureVac N.V. (CVAC) has been on a downward spiral lately with significant selling pressure. After declining 14.3% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.How to Determine if a Stock is OversoldWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a st ...

A downtrend has been apparent in CureVac N.V. (CVAC) lately with too much selling pressure. The stock has declined 15.1% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.Guide to Identifying Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for s ...